SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 17, 2025, reports a transaction in the company's own shares. The filing discloses a share repurchase executed on October 16, 2025, pursuant to a non-discretionary agreement with BNP Paribas SA, announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific buyback transaction rather than general financial performance metrics such as revenue or profit.
- Shares Purchased: 310,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,621.50 GBp; highest price paid was 1,637.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,629.84 GBp.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON.
- Treasury Share Holdings: Following this purchase, GSK holds 251,694,344 ordinary shares in treasury.
- Shares in Issue: 4,063,719,485 ordinary shares (excluding treasury shares).
- Treasury Voting Rights: Treasury shares represent 6.19% of total voting rights.
Material Changes and Program Progress
Since the commencement of the current buyback program on September 30, 2025, the Company has purchased an aggregate of 4,229,500 ordinary shares. The October 16 transaction represents a continuation of this existing program. No other material changes to the company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and Q2 Results for 2025. No new guidance or outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (251,694,344) against the company's latest capital structure disclosures.
- Confirm the remaining authorization under the buyback program announced on September 30, 2025.
- Review the "Risk Factors" section of the 2024 Form 20-F for context on the forward-looking statement disclaimer.
- Check the total voting rights denominator (4,063,719,485) for compliance with FCA Disclosure Guidance and Transparency Rules.